N-gamma-Glutamylglutamine | 10148-81-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-gamma-Glutamylglutamine
• 英文别名: 2-amino-5-[(4-amino-1-carboxy-4-oxobutyl)amino]-5-oxopentanoic acid
• CAS: 10148-81-9
• 化学式: C₁₀H₁₇N₃O₆
• 分子量: 275.26
• InChiKey: JBFYFLXEJFQWMU-UHFFFAOYSA-N

物化性质

• 沸点：
  754.9±60.0 °C(Predicted)
• 密度：
  1.418±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -4.9
• 重原子数：
  19
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  173
• 氢给体数：
  5
• 氢受体数：
  7

安全信息

• 海关编码：
  2924199090

制备方法与用途

H-γ-Glu-Gln-OH 是一种亲水性的肽，可用于药物偶联。由 H-γ-Glu-Gln-OH 组成的载体具有高水溶性、良好的载药能力、出色的生物相容性、较低的毒性和增强的肿瘤靶向及抗肿瘤效果。

文献信息

• Novel method for treating H.pylori infections
  申请人：Gerhard, Markus

  公开号：EP1913955A1

  公开（公告）日：2008-04-23

  Use of a ligand of the gamma-glutamyl transpeptldase of H. pylori (HPGGT) for the manufacture of a drug for the treatment of H. pylori infections, in particular gastro duodenal disorders, whereas the ligand significantly inhibits the HPGGT activity and abrogates the HPGGT dependent suppression of lymphocyte proliferation as assessed in a lymphocyte proliferation assay.

  使用幽门螺杆菌γ-谷氨酰转肽酶（HPGGT）的配体制造治疗幽门螺杆菌感染，特别是胃十二指肠疾病的药物，而配体能显著抑制HPGGT的活性，并减弱在淋巴细胞增殖试验中评估的HPGGT对淋巴细胞增殖的抑制作用。
• Metabolomic profiling of prostate cancer
  申请人：The Regents of the University of Michigan

  公开号：EP2597464A2

  公开（公告）日：2013-05-29

  The present invention relates to cancer markers. In particular, the present invention provides metabolites that are differentially present in prostate cancer. The present invention further provides diagnostic, research, and therapeutic applications targeting cancer specific metabolites.

  本发明涉及癌症标记物。特别是，本发明提供了在前列腺癌中不同程度存在的代谢物。本发明进一步提供了针对癌症特定代谢物的诊断、研究和治疗应用。
• TRYPTOPHAN AS A BIOMARKERS FOR KIDNEY FUNCTION AND METHODS USING THE SAME
  申请人：Metabolon, Inc.

  公开号：EP3410115A1

  公开（公告）日：2018-12-05

  Biomarkers of kidney function and methods for using said biomarkers for assessing kidney function, monitoring kidney function, diagnosing acute kidney injury, and diagnosing chronic kidney disease are provided. Also provided are suites of small molecule entities as biomarkers for chronic kidney disease.

  本研究提供了肾功能生物标志物以及使用上述生物标志物评估肾功能、监测肾功能、诊断急性肾损伤和诊断慢性肾病的方法。此外，还提供了作为慢性肾病生物标志物的小分子实体套件。
• Biomarkers for cardiovascular diseases and methods using the same
  申请人：Metabolon, Inc.

  公开号：US10175233B2

  公开（公告）日：2019-01-08

  Biomarkers relating to cardiovascular disease, including atherosclerosis and cardiomyopathy, are provided, as well as methods for using such biomarkers as biomarkers for cardiovascular disease. In addition, methods for modulating the respective disorders or conditions of a subject are also provided. Also provided are suites of small molecule entities as biomarkers for cardiovascular disease, including atherosclerosis and cardiomyopathy.

  本研究提供了与心血管疾病（包括动脉粥样硬化和心肌病）有关的生物标志物，以及将此类生物标志物用作心血管疾病生物标志物的方法。此外，还提供了调节受试者相应疾病或状况的方法。还提供了作为心血管疾病（包括动脉粥样硬化和心肌病）生物标志物的成套小分子实体。
• Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
  申请人：Metabolon, Inc.

  公开号：US10267777B2

  公开（公告）日：2019-04-23

  Methods are described herein for small molecule biochemical profiling of an individual subject for diagnosis of a disease or disorder, facilitating diagnosis of a disease or disorder, and/or identifying an increased risk of developing a disease or disorder in the individual subject. Aberrant levels of small molecules present in a sample from an individual subject are identified and diagnostic information relevant to the individual subject is obtained based on the identified aberrant levels. The obtained diagnostic information includes one or more of an identification of at least one biochemical pathway associated with the identified subset of the small molecules having aberrant levels, an identification at least one disease or disorder associated with the identified subset of the small molecules having aberrant levels, and an identification of at least one recommended follow up test associated with the identified subset of the small molecules having aberrant levels.

  本文描述了对个体受试者进行小分子生化分析的方法，以诊断疾病或失调，促进疾病或失调的诊断，和/或确定个体受试者罹患疾病或失调的风险增加。确定个体受试者样本中存在的小分子的异常水平，并根据确定的异常水平获得与个体受试者相关的诊断信息。所获得的诊断信息包括：至少一个生化途径的鉴定，该生化途径与所鉴定的具有异常水平的小分子子集相关；至少一种疾病或紊乱的鉴定，该疾病或紊乱与所鉴定的具有异常水平的小分子子集相关；至少一种推荐的后续检测的鉴定，该检测与所鉴定的具有异常水平的小分子子集相关。